Peptide GAlternative Names: Antagonist G; PTL 68001; PTL 68300B
Latest Information Update: 30 May 2007
At a glance
- Originator Cancer Research Technology
- Class Antineoplastics
- Mechanism of Action Substance P inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Colorectal cancer; Pancreatic cancer; Small cell lung cancer